Pulmonary function at diagnosis of amyotrophic lateral sclerosis; Rate of deterioration

P. L. Schiffman, Jerry Belsh

Research output: Contribution to journalArticle

125 Citations (Scopus)

Abstract

The purpose of this study was to determine the degree of respiratory muscle impairment in patients with newly diagnosed amyotrophic lateral sclerosis (ALS) and the subsequent rate of decline of respiratory function. Thirty-one of 36 patients had respiratory muscle weakness at presentation, although only 7 complained of any respiratory symptoms. Vital capacity (percent predicted) was significantly lower in the symptomatic group (55.9±20.3) compared with the asymptomatic group (76.4±21.0). Respiratory muscle impairment as measured by vital capacity (percent predicted) was related to stage of disease at presentation. Rate of decline of respiratory muscle strength as measured by VC (-3.5 percent/month), negative inspiratory pressure (NIF) (+2.9 cm H2O/month), and positive expiratory pressure (PEP) (-3.4 cm H2O/month) tended to be linear with a great deal of interpatient variability. It is concluded that early measurement of respiratory muscle strength in ALS with subsequent follow-up studies may be useful in determining overall prognosis and in decision making.

Original languageEnglish (US)
Pages (from-to)508-513
Number of pages6
JournalCHEST
Volume103
Issue number2
DOIs
StatePublished - Jan 1 1993

Fingerprint

Respiratory Muscles
Amyotrophic Lateral Sclerosis
Lung
Vital Capacity
Muscle Strength
Pressure
Muscle Weakness
Respiratory Rate
Decision Making

All Science Journal Classification (ASJC) codes

  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine
  • Pulmonary and Respiratory Medicine

Cite this

@article{a305884dfb544072b44b73684f66b78b,
title = "Pulmonary function at diagnosis of amyotrophic lateral sclerosis; Rate of deterioration",
abstract = "The purpose of this study was to determine the degree of respiratory muscle impairment in patients with newly diagnosed amyotrophic lateral sclerosis (ALS) and the subsequent rate of decline of respiratory function. Thirty-one of 36 patients had respiratory muscle weakness at presentation, although only 7 complained of any respiratory symptoms. Vital capacity (percent predicted) was significantly lower in the symptomatic group (55.9±20.3) compared with the asymptomatic group (76.4±21.0). Respiratory muscle impairment as measured by vital capacity (percent predicted) was related to stage of disease at presentation. Rate of decline of respiratory muscle strength as measured by VC (-3.5 percent/month), negative inspiratory pressure (NIF) (+2.9 cm H2O/month), and positive expiratory pressure (PEP) (-3.4 cm H2O/month) tended to be linear with a great deal of interpatient variability. It is concluded that early measurement of respiratory muscle strength in ALS with subsequent follow-up studies may be useful in determining overall prognosis and in decision making.",
author = "Schiffman, {P. L.} and Jerry Belsh",
year = "1993",
month = "1",
day = "1",
doi = "https://doi.org/10.1378/chest.103.2.508",
language = "English (US)",
volume = "103",
pages = "508--513",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

Pulmonary function at diagnosis of amyotrophic lateral sclerosis; Rate of deterioration. / Schiffman, P. L.; Belsh, Jerry.

In: CHEST, Vol. 103, No. 2, 01.01.1993, p. 508-513.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pulmonary function at diagnosis of amyotrophic lateral sclerosis; Rate of deterioration

AU - Schiffman, P. L.

AU - Belsh, Jerry

PY - 1993/1/1

Y1 - 1993/1/1

N2 - The purpose of this study was to determine the degree of respiratory muscle impairment in patients with newly diagnosed amyotrophic lateral sclerosis (ALS) and the subsequent rate of decline of respiratory function. Thirty-one of 36 patients had respiratory muscle weakness at presentation, although only 7 complained of any respiratory symptoms. Vital capacity (percent predicted) was significantly lower in the symptomatic group (55.9±20.3) compared with the asymptomatic group (76.4±21.0). Respiratory muscle impairment as measured by vital capacity (percent predicted) was related to stage of disease at presentation. Rate of decline of respiratory muscle strength as measured by VC (-3.5 percent/month), negative inspiratory pressure (NIF) (+2.9 cm H2O/month), and positive expiratory pressure (PEP) (-3.4 cm H2O/month) tended to be linear with a great deal of interpatient variability. It is concluded that early measurement of respiratory muscle strength in ALS with subsequent follow-up studies may be useful in determining overall prognosis and in decision making.

AB - The purpose of this study was to determine the degree of respiratory muscle impairment in patients with newly diagnosed amyotrophic lateral sclerosis (ALS) and the subsequent rate of decline of respiratory function. Thirty-one of 36 patients had respiratory muscle weakness at presentation, although only 7 complained of any respiratory symptoms. Vital capacity (percent predicted) was significantly lower in the symptomatic group (55.9±20.3) compared with the asymptomatic group (76.4±21.0). Respiratory muscle impairment as measured by vital capacity (percent predicted) was related to stage of disease at presentation. Rate of decline of respiratory muscle strength as measured by VC (-3.5 percent/month), negative inspiratory pressure (NIF) (+2.9 cm H2O/month), and positive expiratory pressure (PEP) (-3.4 cm H2O/month) tended to be linear with a great deal of interpatient variability. It is concluded that early measurement of respiratory muscle strength in ALS with subsequent follow-up studies may be useful in determining overall prognosis and in decision making.

UR - http://www.scopus.com/inward/record.url?scp=0027412223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027412223&partnerID=8YFLogxK

U2 - https://doi.org/10.1378/chest.103.2.508

DO - https://doi.org/10.1378/chest.103.2.508

M3 - Article

VL - 103

SP - 508

EP - 513

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -